References
- Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157–203.
- Glennon RA. Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem 2003;46:2795–2812.
- Brian JJ, Thomas PB. The medical benefit of 5-HT research. Pharmacol Biochem Behav 2002;71:555–568.
- Christopher NJ, Mahmood A, Neil DM. 5-HT6 receptor antagonists: prospects for the treatment of cognitive disorders including dementia. Curr Opinion Drug Dis Dev 2008;11:642–654.
- Holenz J, Pauwels PJ, Díaz JL, Mercè R, Codony X, Buschmann H. Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents. Drug Discov Today 2006;11:283–299.
- Liu KG, Robichaud AJ. 5-HT6 medicinal chemistry. Int Rev Neurobiol 2010;94:1–34.
- Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther 2008;117:207–231.
- Upton N, Chuang TT, Hunter AJ, Virley DJ. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s disease. Neurotherapeutics 2008;5:458–469.
- Witty D, Ahmed M, Chuang TT. Advances in the design of 5-HT6 receptor ligands with therapeutic potential. Prog Med Chem 2010;48:161–224.
- Rossé G, Schaffhauser H. 5-HT6 receptor antagonists as potential therapeutics for cognitive impairment. Curr Top Med Chem 2010;10:207–221.
- Robichaud AJ. Identification of SAM-531 (WAY-262531), a selective 5-HT6 antagonist for the treatment of cognitive dysfunction associated with schizophrenia and Alzheimer’s disease. 239th ACS National Meeting and Exposition. San Francisco, CA, MEDI-34, 21–25 March 2010.
- Johnson CN. The impact of PET on the discovery of 742457, a brain-penetrant 5-HT6 receptor antagonist for symptomatic treatment of Alzheimer’s disease. CHI 13th International Molecular Medicine Triconference, San Francisco, USA, 2006.
- Chuang A, Foley A, Pugh PL. 5-HT6 receptor antagonist SB-742457 as a novel cognitive enhancing agent for Alzheimer’s disease. Alzheimers Dement 2006;2:S631.
- Mancinelli A. Pharmacokinetics of 5-HT6 receptor ligands. Int Rev Neurobiol 2010;94:153–172.
- Pineiro-Nunez MM, Bauzon DD, Bymaster FP, Chen Z, Chernet E, Clay MP et al. Discovery and SAR studies of 2,6-difluorobenzenesulfonic acid 1-methyl-3-(1-methylpiperidin-4-yl)-1H-indol-5-yl ester, a novel and potent 5-HT6 antagonist for the treatment of cognitive deficit. Abstracts of Papers, 229th ACS National Meeting, San Diego, CA, United States, MEDI-282, 13–17 March 2005.
- Arnt J, Andersen BB, Bymaster FP, Chohen MP. 2nd Biennial Schizophrenia International Research Conference (SIRS), Florence, Italy, 10–14 April 2010.
- Nirogi R, Kandikere V, Mudigonda K, Bhyrapuneni G, Jasti V. Human phase-1 Multiple Ascending Dose (MAD) study, safety, tolerability and pharmacokinetics of SUVN-502, a 5-HT6 receptor antagonist. Alzheimers Dement 2009;5:250–251.
- Glennon RA, Lee M, Rangisetty JB, Dukat M, Roth BL, Savage JE et al. 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem 2000;43:1011–1018.
- Russell MG, Baker RJ, Barden L, Beer MS, Bristow L, Broughton HB et al. N-Arylsulfonylindole derivatives as serotonin 5-HT(6) receptor ligands. J Med Chem 2001;44:3881–3895.
- Mooradian A, Dupont PE, Hlavec AG, Aceto MD, Pearl J. 3-Aminotetrahydrocarbazoles as a new series of central nervous system agents. J Med Chem 1977;20:487–492.
- Abate C, Kolanos R, Dukat M, Setola V, Roth BL, Glennon RA. Interaction of chiral MS-245 analogs at h5-HT6 receptors. Bioorg Med Chem Lett 2005;15:3510–3513.
- Demchyshyn LL, Wilson JM, Maclean NA, Wang H, Black C, DeLannoy I et al. ALX-1161: pharmacological properties of a potent and selective 5-HT6 receptor antagonist. 31st Annual Meeting of the Society for Neuroscience, San Diego, CA, 2001.
- Slassi A, Edwards L, O’Brien A, Xin T, Tehim A. Preparation of 3-(2-pyrrolidinylmethyl)indoles as 5-HT6 antagonists. WO 9947516.
- Liu KG, Lo JR, Comery TA, Zhang GM, Zhang JY, Kowal DM et al. A regiospecific synthesis of a series of 1-sulfonyl azepinoindoles as potent 5-HT6 ligands. Bioorg Med Chem Lett 2008;18:3929–3931.
- Cole DC, Lennox WJ, Stock JR, Ellingboe JW, Mazandarani H, Smith DL et al. Conformationally constrained N1-arylsulfonyltryptamine derivatives as 5-HT6 receptor antagonists. Bioorg Med Chem Lett 2005;15:4780–4785.
- Ennaceur A, Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 1988;31:47–59.
- Speeter ME, Anthony WC. The action of oxalyl chloride on indoles: a new approach to tryptamines. J Am Chem Soc 1954;76:6208–6210.
- Heck RF. Arylation, methylation and carboxyalkylation of olefines by Group VIII metal derivatives. J Am Chem Soc 1968;90:5518–5526.
- Heck RF, Noley JP Jr. Palladium-catalysed vinylic hydrogen substitution reactions with aryl, benzyl and styryl halides. J Org Chem 1972;37:2320–2322.
- Meijere AD, Meyer FE. Fine feathers make fine birds: the Heck reaction in modern garb. Angew Chem Int Ed Engl 1994;33:2379–2411.